Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anifrolumab in Systemic Sclerosis
NCT05925803Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Nov 2023
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 23
01
Overview
A Phase 3 trial of anifrolumab in systemic sclerosis (SSc), sponsored by AstraZeneca. Started Nov 2023; status: active, not recruiting.
02
Drugs
anifrolumab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT05925803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05925803.